JP2025513071A5 - - Google Patents

Info

Publication number
JP2025513071A5
JP2025513071A5 JP2024560501A JP2024560501A JP2025513071A5 JP 2025513071 A5 JP2025513071 A5 JP 2025513071A5 JP 2024560501 A JP2024560501 A JP 2024560501A JP 2024560501 A JP2024560501 A JP 2024560501A JP 2025513071 A5 JP2025513071 A5 JP 2025513071A5
Authority
JP
Japan
Prior art keywords
diabetes
disease
pharmaceutical composition
composition according
onset
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/087997 external-priority patent/WO2023198140A1/en
Publication of JP2025513071A publication Critical patent/JP2025513071A/ja
Publication of JP2025513071A5 publication Critical patent/JP2025513071A5/ja
Pending legal-status Critical Current

Links

JP2024560501A 2022-04-14 2023-04-13 ヘテロ環式glp-1アゴニスト Pending JP2025513071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/086863 2022-04-14
CN2022086863 2022-04-14
PCT/CN2023/087997 WO2023198140A1 (en) 2022-04-14 2023-04-13 Heterocyclic glp-1 agonists

Publications (2)

Publication Number Publication Date
JP2025513071A JP2025513071A (ja) 2025-04-22
JP2025513071A5 true JP2025513071A5 (cg-RX-API-DMAC7.html) 2026-04-15

Family

ID=86331708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560501A Pending JP2025513071A (ja) 2022-04-14 2023-04-13 ヘテロ環式glp-1アゴニスト

Country Status (5)

Country Link
US (1) US20250250269A1 (cg-RX-API-DMAC7.html)
EP (1) EP4508047B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513071A (cg-RX-API-DMAC7.html)
CN (1) CN119255988A (cg-RX-API-DMAC7.html)
WO (1) WO2023198140A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039528A (en) 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6628343B1 (en) 1997-05-23 2003-09-30 Sony Corporation Television signal reception circuit, automatic phase shift control circuit and equal amplitude addition circuit
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF
AU2001288690A1 (en) 2000-09-05 2002-03-22 Odyssey Pharmaceuticals Llc Two-component anti-emetic composition comprising dexamethasone and metoclopramide
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
WO2003072197A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Acc inhibitors
US6673792B1 (en) 2002-07-11 2004-01-06 Upchuck, Llc Broad-spectrum anti-emetic compositions and associated methods
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ ノルディスク アクティーゼルスカブ 新規なglp−1化合物
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
US20050287100A1 (en) 2004-06-08 2005-12-29 Lebre Caroline Cosmetic composition comprising a semi-crystalline polymer and a dispersion of polymer in fatty phase
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
JP2008536881A (ja) 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Glp−1分子と制吐剤との医薬製剤
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008065508A1 (en) 2006-11-29 2008-06-05 Pfizer Products Inc. Spiroketone acetyl-coa carboxylase inhibitors
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
EP2072050A1 (en) 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
EP2297164A1 (en) 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
ES2380408T3 (es) 2008-08-28 2012-05-11 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
WO2010103437A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
GEP20135907B (en) 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
US20120021979A1 (en) 2010-06-24 2012-01-26 Vanderbilt University GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
DK2621493T3 (en) 2010-09-30 2016-10-24 Pfizer N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS
US20120101089A1 (en) 2010-10-26 2012-04-26 Ashwani Agarwal Anti-Emetic Substance
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー/エス Glp−1誘導体
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
JP6573604B2 (ja) 2013-06-11 2019-09-11 セルジーン インターナショナル ツー エスエーアールエル 新規なglp−1レセプターモジュレーター
CN107074820B (zh) 2014-07-25 2021-05-18 赛尔基因第二国际有限公司 Glp-1受体调节剂
GB201506116D0 (en) 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
EP3723743A4 (en) 2017-12-15 2021-09-08 Montero Gida Sanayi Ve Ticaret Anonim Sirketi DRUG COMBINATION INCLUDING DAPOXETINE, PHOSPHODIESTERASE TYPE 5 INHIBITOR AND ANTIEMETIC AGENT
JP7161605B2 (ja) 2018-08-31 2022-10-26 ファイザー・インク Nash/nafldおよび関連疾患の治療のための組合せ
EA202191432A1 (ru) * 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
EP3890748A4 (en) 2018-12-05 2022-12-21 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
CA3140972C (en) 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
JP2023546055A (ja) * 2020-10-13 2023-11-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト

Similar Documents

Publication Publication Date Title
JP2025506474A5 (cg-RX-API-DMAC7.html)
JP2025504508A5 (cg-RX-API-DMAC7.html)
JP2025506473A5 (cg-RX-API-DMAC7.html)
JP2025510741A5 (cg-RX-API-DMAC7.html)
US12036210B2 (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
JP2023515404A5 (cg-RX-API-DMAC7.html)
JP2023524493A5 (cg-RX-API-DMAC7.html)
JP2023540609A5 (cg-RX-API-DMAC7.html)
US8791266B2 (en) Thyroid hormone β receptor agonist
US20240294525A1 (en) Compounds as glp-1 receptor agonists and uses thereof
US11648216B2 (en) Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
JP2021091683A5 (cg-RX-API-DMAC7.html)
TW200835482A (en) GPCR agonists
JP2023546125A5 (cg-RX-API-DMAC7.html)
CN121985948A (zh) Glp-1r激动剂的制剂及其制备方法
CA3133768A1 (en) Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia
TW201105336A (en) Combined medicine of pyrazole derivative and biguanide drug
TW201904968A (zh) 以三唑并吡啶治療rbp4相關疾病之方法
KR20240116482A (ko) 과혈당증 및 2형 당뇨병 치료를 위한 (r)-2-(tert-부틸아미노)-1-(5-플루오로피리딘-3-일)-에탄-1-올 헤미-타르트레이트 염의 결정질 형태
JP2023543924A5 (cg-RX-API-DMAC7.html)
JP6782763B2 (ja) 新規のピリジニウム化合物
US10428055B2 (en) Substituted piperidines having GPR119 agonistic activity
JP2019520381A (ja) 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物
KR20180101671A (ko) 헤테로아릴이 치환된 2-페닐이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 GLP-1 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
JP5252585B2 (ja) 代謝障害の治療のための化合物